Materials Design Analysis Reporting (MDAR) Checklist for Authors

The MDAR framework establishes a minimum set of requirements in transparent reporting applicable to studies in the life sciences (see Statement of Task: doi:10.31222/osf.io/9sm4x.). The MDAR checklist is a tool for authors, editors and others seeking to adopt the MDAR framework for transparent reporting in manuscripts and other outputs. Please refer to the MDAR Elaboration Document for additional context for the MDAR framework.

Materials

Antibodies	Yes (indicate where provided: section/paragraph)	n/a
For commercial reagents, provide supplier name, catalogue number and RRID, if available.	- Leica CM1900 (line 48) - MP Biomedicals FastPrep-24 (line 50) - IBM SPSS Statistics 25 (line 70)	

Cell materials	Yes (indicate where provided: section/paragraph)	n/a
Cell lines: Provide species information, strain. Provide accession number in repository **OR** supplier name, catalog		--- Not used
Primary cultures: Provide species, strain, sex of origin,		--- Not used

Experimental animals	Yes (indicate where provided: section/paragraph)	n/a
Laboratory animals: Provide species, strain, sex, age, genetic modification status. Provide accession number in repository **OR** supplier name, catalog		--- Not used
Animal observed in or captured from the field: Provide species, sex and age		--- Not used
Model organisms: Provide Accession number in repository		--- Not used

Plants and microbes	Yes (indicate where provided: section/paragraph)	n/a
Plants: provide species and strain, unique accession number if available, and source (including location for		--- Not used
Microbes: provide species and strain, unique accession		--- Not used

Human research participants	Yes (indicate where provided: section/paragraph)	n/a
Identify authority granting ethics approval (IRB or equivalent committee(s), provide reference	- Methods (line 29) - Ethical statement (line 171)	
Provide statement confirming informed consent obtained from	- Methods (line 30) - Ethical statement (line 172)	
Report on age and sex for all study participants.		Incomplete because of partly old data when age and sex were not recorded. *If you wish to receive the recorded part, please let us know. Thank you.*

Design

Study protocol	Yes (indicate where provided:	n/a
For clinical trials, provide the trial registration number **OR** cite DOI in manuscript.		-

Laboratory protocol	Yes (indicate where provided:	n/a
Provide DOI or other citation details if detailed step-by-step protocols are available.		-

Experimental study design (statistics details)	Yes (indicate where provided:	n/a
State whether and how the following have been done**, or** if they were not carried out.	Methods section (lines 29-42)	
Sample size determination		-
Randomisation	No randomization, line 34	
Blinding	No blinding, line 34	
Inclusion/exclusion criteria	- Line 32	

Sample definition and in-laboratory replication	Yes (indicate where provided:	n/a
State number of times the experiment was replicated in laboratory	46 times (line 89)	
Define whether data describe technical or biological replicates	*Unfortunately, I do not fully understand your definition. Each time it was another tissue sample from another patient, so I assume it is a biological replicate. I hope, I was able to answer your question.*	

Ethics	Yes (indicate where provided:	n/a
Studies involving human participants: State details of authority granting ethics approval (IRB or equivalent committee(s), provide reference number for approval.		--- Not used
Studies involving experimental animals: State details of authority granting ethics approval (IRB or equivalent committee(s), provide reference number for approval.		--- Not used
Studies involving specimen and field samples: State if relevant permits obtained, provide details of authority approving study; if none were required, explain why.	- Line 29-31 - Line 169	

Dual Use Research of Concern (DURC)	Yes (indicate where provided:	n/a
If study is subject to dual use research of concern, state the authority granting approval and reference number for the regulatory approval		---

Analysis

Attrition	Yes (indicate where provided: section/paragraph)	n/a
State if sample or data point from the analysis is excluded, and whether the criteria for exclusion were determined and specified in advance.		---

Statistics	Yes (indicate where provided: section/paragraph)	n/a
Describe statistical tests used and justify choice of tests.	- Line 70-86	

Data Availability	Yes (indicate where provided: section/paragraph)	n/a
State whether newly created datasets are available, including protocols for access or restriction on access.		---
If data are publicly available, provide accession number in repository or DOI or URL.		---
If publicly available data are reused, provide accession number in repository or DOI or URL, where possible.		---

Code Availability	Yes (indicate where provided: section/paragraph)	n/a
For all newly generated code and software essential for replicating the main findings of the study:		--
State whether the code or software is available.		---
If code is publicly available, provide accession number in repository, or DOI or URL.		---

Reporting

Adherence to community standards	Yes (indicate where provided: section/paragraph)	n/a
MDAR framework recommends adoption of discipline-specific guidelines, established and endorsed through community initiatives. Journals have their own policy about requiring specific guidelines and recommendations to complement MDAR.		--
State if relevant guidelines (eg., ICMJE, MIBBI, ARRIVE) have been followed, and whether a checklist (eg., CONSORT, PRISMA, ARRIVE) is provided with the manuscript.	Documents of Conflict of Interest (DOI) following ICMJE were attached at first submission. In case you need these again, please contact us.	

Article information: http://dx.doi.org/10.21037/atm-20-6307